News 2017

Nutrileads, NIZO Food Research and Friesland Campina win prestigious EFRO Grant

Date: 08/06/2017

7 June 2017, Wageningen, The Netherlands – NUTRILEADS B.V., a Dutch Nutrition & Health startup, together with NIZO food research (consortium leader) and Friesland Campina, has been awarded a €3,7 million EFRO project called CHALLENGE. (more…)

argenx announces closing of NASDAQ IPO

Date: 23/05/2017

23 May 2017, Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), announced today the closing of its initial public offering in the United States (the “Offering”) of 6,744,750 American Depositary Shares (“ADSs”), at a price to the public of $17.00 per ADS, for gross proceeds of approximately $114.7 million. (more…)

argenx raises approximately $100 million gross proceeds with NASDAQ IPO

Date: 18/05/2017

18 May 2017, Breda, the Netherlands / Ghent, Belgium – argenx (Euronext Brussels: ARGX, Nasdaq: ARGX) announced today the pricing of its initial public offering in the United States (the “Offering”) with anticipated gross proceeds totalling approximately $100 million from the sale of 5,865,000 American Depository Shares (“ADSs”), at a price to the public of $17.00 per ADS. (more…)

NutriLeads closes series A round to advance the development of its lead nutritional ingredient supporting immune function

Date: 29/03/2017

29 March 2017, Wageningen, The Netherlands -Dutch nutritional health ingredients startup NUTRILEADS B.V. today announces the successful closing of a Series A financing round with existing shareholders DSM VENTURING, PPM OOST, SHIFT INVEST and THUJA CAPITAL. (more…)

Argenx announces collaboration with Broteio Pharma to develop therapeutic antibody for severe autoimmune diseases

Date: 21/03/2017

21 March 2017, Breda, the Netherlands/Ghent, Belgium – argenx (Euronext Brussels: ARGX) today announced that it has entered into a new collaboration with Broteio Pharma B.V. to develop an antibody against a novel target in the complement cascade with therapeutic potential in autoantibody- and complement-mediated indications including autoimmune haemolytic anaemia (AIHA) and antibody mediated rejection (AMR) following organ transplantation. (more…)

Cristal Therapeutics successfully closes €12.8 million financing round

Date: 19/01/2017

19 January 2016, Maastricht, The Netherlands – Cristal Therapeutics today announced the closing of a €12.8 million financing round. The financing comes from a consortium headed by Dutch oncology investor Aglaia BioMedical Ventures and Belgian DROIA Oncology Ventures (more…)

Newspaper articles: Hemics install first Handscan device in Dutch hospital

Date: 10/01/2017

10 January 2017, Eindhoven, The Netherlands – The regional Dutch newspaper Eindhovens Dagblad reported on Hemics installing a first Handscan device in a major Dutch hospital.  (more…)